Abstract:Objective To investigate the feasibility of Montelukast Sodium as an adjuvant treatment in children with Mycoplasma pneumonia by observing their clinical manifestations.Methods Sixty-two children with Mycoplasma pneumonia who were treated in our hospital from August 2014 to July 2016 were selected as subjects.They were divided into the control group (n=30)and observation group (n=32)according to the random number table method.In the control group,pediatric patients were treated with intravenous infusion of Azithromycin and aerosol inhalation of Budesonide,while in the observation group,on the basis of the control group,Montelukast Sodium as oral administration was added.The relative clinical data including total therapeutic effectiveness rate,remission time of relevant symptoms,hospital stay,incidence of complications,and blood gas analysis were observed and recorded in the two groups.Results The therapeutic effectiveness rate in the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).The remission time of cough,temperature lowering,disappearance of rales and hospital stay in the observation group were all shorter compared with those in the control group,the incidence of extrapulmonary complications was also lower than that of the control group,and the differences were statistically significant(P<0.05).The forced expiratory volume in one second(FEV1),the forced expiratory volume in one second/forced vital capacity (FEV1/FVC),maximum expiratory flow (PEF)were all superior to those in the control group,and the differences were statistically significant(P<0.05).The content of PO2in the observation group was higher than that in the control group,and the content of PCO2was lower than that in the control group,which were displayed statistical significance(P<0.05).Conclusion In the treatment of children with Mycoplasma pneumonia,Montelukast Sodium can obtain a remarkable effect by greatly promoting therapeutic progress and improving the relevant clinical symptoms,and facilitating the recovery of lung function in children in high safety,which can be popularized and applied in clinic.
陶梦婕. 孟鲁司特钠辅助治疗儿童支原体肺炎的可行性分析[J]. 中国当代医药, 2018, 25(10): 147-149转153.
TAO Meng-jie. Feasibility analysis of Montelukast Sodium as an adjuvant treatment for Mycoplasma pneumonia in children. 中国当代医药, 2018, 25(10): 147-149转153.